Recent Updates
Recently added Catalysts
FBLG Positive Sentiment Score: 80/100

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

Key Takeaway: FibroBiologics, a clinical-stage biotechnology company, will present its research on fibroblast-based therapies for chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting. Chief Scientific Officer Hamid Khoja will discuss the company's progress in utilizing fibroblasts for possible treatments, emphasizing their regenerative properties. The conference will take place in Freiburg, Germany, from March 26-28, 2025, providing a platform to showcase advancements in extracellular matrix biology.

Market Sentiment Analysis

POSITIVE FACTORS

  • FibroBiologics is presenting innovative research on fibroblast therapies.
  • The presentation could enhance collaboration and visibility in the field.
  • FibroBiologics has a strong focus on chronic disease treatment with significant patent holdings.

Full Press Release Details

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellular matrix biology.
Dr. Khoja commented, “Fibroblasts are a critical component of the extracellular matrix with regenerative and immunomodulatory properties. Our presentation will detail the progress we’ve made in expanding our portfolio and targeting additional indications by leveraging the unique potential of fibroblasts.”
Details of the conference and presentations are as follows:
The German-Nordic Joint Extracellular Matrix Meeting
Presentation Title: Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation.
Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics
Location: Otto-Krayer Haus, Albertstrasse 25, Freiburg, Germany
Date and Time: Thursday, March 27, at 10:25 a.m. to 12:00 p.m. Central European Time
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

Frequently Asked Questions

What is the focus of FibroBiologics?

FibroBiologics focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts.

Who will present at the German-Nordic meeting?

Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present.

When is Dr. Khoja's presentation scheduled?

Dr. Khoja's presentation is on March 27, 2025, from 10:25 a.m. to 12:00 p.m. CET.

What are fibroblasts' properties?

Fibroblasts have regenerative and immunomodulatory properties within the extracellular matrix.

Where is FibroBiologics located?

FibroBiologics is based in Houston, Texas.

Last updated: Mar 21, 2025